Abstract:Glioblastoma multiforme (GBM) is known as the most aggressive and prevalent brain tumor with a high mortality rate. It is reported in people who are as young as 10 years old to as old as over 70 years old, exhibiting inter and intra tumor heterogeneity. There are several genomic and proteomic investigations that have been performed to find the unexplored potential targets of the drug against GBM. Therefore, certain effective targets have been taken to further validate the studies embarking on the robustness in the field of medicinal chemistry followed by testing in clinical trials. Also, The Cancer Genome Atlas (TCGA) project has identified certain overexpressed targets involved in the pathogenesis of GBM in three major pathways, i.e., tumor protein 53 (p53), retinoblastoma (RB), and receptor tyrosine kinase (RTK)/rat sarcoma virus (Ras)/phosphoinositide 3-kinase (PI3K) pathways. This review focuses on the compilation of recent developments in the fight against GBM thus, directing future research into the elucidation of pathogenesis and potential cure for GBM. Also, it highlights the potential biomarkers that have undergone extensive research and have promising prognostic and predictive values. Additionally, this manuscript analyses the advent of gene therapy and immunotherapy, unlocking the way to consider treatment approaches other than, or in addition to, conventional chemo-radiation therapies. This review study encompasses all the relevant research studies associated with the pathophysiology, occurrence, diagnostic tools, and therapeutic intervention for GBM. It highlights the evolution of various therapeutic perspectives against GBM from the most conventional form of radiotherapy to the recent advancement of gene/cell/immune therapy. Further, the review focuses on various targeted therapies for GBM including chemotherapy sensitization, radiotherapy, nanoparticles based, immunotherapy, cell therapy, and gene therapy which would offer a comprehensive account for exploring several facets related to GBM prognostics.

Targeting the Endocannabinoid System Present in the Glioblastoma Tumour Microenvironment as a Potential Anti-Cancer Strategy

The antitumor action of endocannabinoids in the tumor microenvironment of glioblastoma

Improving the Biopharmaceutical Properties of Cannabinoids in Glioblastoma Multiforme Therapy With Nanotechnology: A Drug Delivery Perspective

Novel insights into astrocyte-mediated signaling of proliferation, invasion and tumor immune microenvironment in glioblastoma

Cannabinoids in the treatment of glioblastoma

Nanotherapeutic treatment of the invasive glioblastoma tumor microenvironment

Innovative drug delivery strategies for targeting glioblastoma: overcoming the challenges of the tumor microenvironment

Nanomedicine facilitated cell signaling blockade: difficulties and strategies to overcome glioblastoma

Contemporary strategies in glioblastoma therapy: Recent developments and innovations

Immunomodulatory signalling networks in glioblastoma multiforme: a comprehensive review of therapeutic approaches

Nanomedicines Targeting Glioma Stem Cells

The application of cannabidiol in the treatment of glioblastoma

Targeted Nanotechnology in Glioblastoma Multiforme

New phase therapeutic pursuits for targeted drug delivery in glioblastoma multiforme

Targeting Innate Immunity in Glioma Therapy

Potential of Nanocarrier-Associated Approaches for Better Therapeutic Intervention in the Management of Glioblastoma

Brain-targeted Nano-architectures for Efficient Drug Delivery and Sensitization in Glioblastoma

"Targeting the Tumor and Tumor Microenvironment"

Targeting the undruggable in glioblastoma using nano-based intracellular drug delivery

Harnessing the role of aberrant cell signaling pathways in glioblastoma multiforme: a prospect towards the targeted therapy

Targeted therapies for Glioblastoma multiforme (GBM): State‐of‐the‐art and future prospects